Mainz Biomed N.V. Overview
Pro stress-test →Mainz Biomed develops and sells in-vitro diagnostic tests for early detection of cancer, with its flagship product ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. Founded in 2008 and based in Mainz, Germany, the company is advancing next-generation cancer screening solutions with expanded pipeline candidates.
Strategic Profile
Pro stress-test →The company is focusing on a next-generation screening test with mRNA biomarkers that detects both colorectal cancer and advanced adenomas, seeking reimbursement and guideline inclusion. Mainz Biomed has a collaboration agreement with Thermo Fisher Scientific for colorectal cancer screening product development and commercialization. In 2025, the company entered into a licensing agreement with Liquid Biosciences for mRNA biomarkers enabling a blood-based pancreatic cancer screening test for potential FDA applications.
Competitive Landscape
Pro stress-test →Mainz Biomed competes in the non-invasive cancer screening market against companies offering FIT tests, colonoscopy alternatives, and emerging blood-based screening platforms. Competitors include Check-Cap, ENDRA Life Sciences, and established IVD players. Differentiation rests on proprietary mRNA biomarker technology and multi-cancer capability development.
Industry Context
Mainz Biomed N.V. operates in Molecular Genetics Diagnostics / In-Vitro Diagnostics (IVD) - Cancer Screening.
Key facts
Founded: 2008 · Headquarters: Mainz, Germany · Market cap: $95.7M